PD-L1 RNA levels in CTCs may be an accurate predictor of response and a monitorable biomarker that dynamically changes in patients with HCC during Atezo/Bev treatment, reflecting the treatment response. The gene discussed is CD274; the disease is hepatocellular carcinoma.